Compare Li Auto Inc (LI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Revvity Inc — how do they compare? Li Auto Inc trades at $12.51 (market cap $12.28B), while Revvity Inc trades at $115.89 (market cap $12.91B). The key difference: Li Auto Inc and Revvity Inc are close in size by market cap, and Revvity Inc pays a 0.24% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| LI | RVTY | |
|---|---|---|
Market Cap | $12.28B | $12.91B |
Sector | Consumer Cyclical | Technology |
52-Week High | $26.69 | $117.75 |
52-Week Low | $11.74 | $82.26 |
Enterprise Value | $1.11B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.505, down 2.61% on the day, with a bearish technical signal and mixed earnings performance. Recent quarterly results show misses on EPS estimates, while revenue declined to $112.31 billion in 2025. The company maintains strong delivery growth, with 30,468 vehicles delivered in July 2026, but faces intense competition in China's EV market. Cash flow trends indicate operational challenges, with negative net cash flow of $9.00 billion in 2025.
Outlook remains cautious due to profitability pressures and competitive headwinds, though analyst consensus suggests moderate upside to a $14.80 price target. Key risks include execution on new model launches and macroeconomic volatility in the EV sector. The stock's current valuation metrics, such as a P/S of 0.83, may appeal to value-oriented investors if operational improvements materialize.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
